The Search for Genetic Risk Factors of Type 2 Diabetes Mellitus by Park, Kyong Soo
D I A B E T E S  &  M E T A B O L I S M   J O U R N A L
This is an Open Access article distributed under the terms of the Creative Commons At-
tribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Copyright © 2011 Korean Diabetes Association  http://e-dmj.org
Diabetes Metab J 2011;35:12-22
The Search for Genetic Risk Factors of Type 2 Diabetes 
Mellitus
Kyong Soo Park
Department of Internal Medicine and Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University College of Medicine, 
Seoul, Korea
Type 2 diabetes mellitus (T2DM) is caused by complex interplay between multiple genetic and environmental factors. The three 
major approaches used to identify the genetic susceptibility include candidate gene approach, familial linkage analysis and ge-
nome-wide association analysis. Recent advance in genome-wide association studies have greatly improved our understanding 
of the pathophysiology of T2DM. As of the end of 2010, there are more than 40 confirmed T2DM-associated genetic loci. Most 
of the T2DM susceptibility genes were implicated in decreased β-cell function. However, these genetic variations have a modest 
effect and their combination only explains less than 10% of the T2DM heritability. With the advent of the next-generation sequenc-
ing technology, we will soon identify rare variants of larger effect as well as causal variants. These advances in understanding the 
genetics of T2DM will lead to the development of new therapeutic and preventive strategies and individualized medicine.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a multi-factorial disease 
caused by complex interplay between genetic predisposition 
and environmental factors [1]. Environmental factors such as 
increased calorie intake, physical inactivity or obesity certainly 
contribute to the recent diabetes epidemic. However, genetic 
factors are also key determinants of the individual susceptibil-
ity to T2DM. The importance of genetic risk factors for T2DM 
is supported by two major findings. First, there are ethnic dif-
ferences in the prevalence of T2DM. Asians or Pima Indians 
residing in Western countries have at least a two-fold increased 
risk of T2DM compared to European natives [2]. Second, there 
is strong family history of T2DM. The offspring of T2DM par-
ents have 40% chance of having T2DM, which is a 6-fold in-
creased risk compared to a population risk of 7% [2]. 
  There has been a tremendous effort to reveal the genetic 
predisposition of T2DM over the past 30 years or so. The three 
approaches adopted for identifying genetic risk factors include: 
1) focusing on linkage peaks from family studies, 2) targeting 
candidate genes on the biological basis, and 3) genome-wide 
association analysis. Since the recent advent of genome-wide 
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association studies (GWAS), there has been remarkable prog-
ress in our understanding of the genetic basis of T2DM. More 
than 40 genetic variations that modify the risk of T2DM de-
velopment have been identified. In this article, I will review 
the current approaches and progress in understanding the ge-
netics of T2DM.
FAMILY-BASED LINKAGE ANALYSIS
Family-based linkage analysis relies on genetic markers in a 
family pedigree to identify the chromosomal regions showing 
linkage with T2DM. This approach is most useful when the 
disease under investigation follows a monogenic form of in-
heritance. Causative genetic variations of several monogenic 
forms of diabetes, including maturity-onset diabetes of the 
young, neonatal diabetes and maternally inherited diabetes and 
deafness were successfully identified using this approach [3-5]. 
However, this approach failed to identify causative genes for 
the common form of T2DM. There have been several reports 
suggesting linkage peaks near CAPN10 and ACRP30 [6,7]. 
Unfortunately, these results were not consistent across the 
study population and no high-risk variation was found to be 
associated with T2DM near these regions. 
THE CANDIDATE GENE APPROACH
The candidate gene approach refers to case-control association 
studies focusing on specific candidate gene or a selected genetic 
region, chosen based on known biological function. More than 
hundreds of candidate genes have been investigated by this ap-
proach. However, only a few genes such as PPARG and KCNJ11 
have been shown to be associated with T2DM [8,9]. 
  The PPARG gene encodes the peroxisome proliferator-acti-
vated receptor γ, which plays a fundamental role in adipogen-
esis and insulin sensitivity by regulating transcriptional activi-
ty of various genes. A variation with proline at the 12th amino 
acid (P12A) was confirmed to be associated with a modest 
(odds ratio [OR] of 1.25), but significant increase in T2DM 
risk [8]. 
  The KCNJ11 gene, located on the short arm of chromosome 
11, encodes the pore-forming subunit of the ATP-sensitive 
potassium channel Kir6.2 of the pancreatic β-cells. Gain-of-
function mutations of KCNJ11 open the potassium channel 
and inhibit the depolarization of β-cells, leading to a defect in 
insulin secretion [10]. Studies in various populations have con-
sistently reported that substitution of lysine for glutamic acid 
at the 23rd amino acid (E23K) is associated with an increased 
risk of T2DM [11,12]. In recent reports of large-scale associa-
tion studies and meta-analyses, the E23K variation was found 
to increase the risk of T2DM with an OR of 1.15 [9]. 
  The most significant finding derived from the candidate 
gene approach is the strong association of TCF7L2 gene [13]. 
This gene was first discovered to increase the risk of T2DM 
through an effort to pinpoint the previously reported linkage 
peak [14]. The association between rs7903146T, an intronic 
variation, with T2DM was replicated in almost all ethnic groups 
and revealed to have the strongest effect in Europeans (OR, 
1.46) [15-17]. A global meta-analysis showed that this varia-
tion had an OR of 1.45 and P-value of 5.4×10
-140 in a compari-
son of more than 46,000 cases and controls [18]. However, this 
allele had a significantly lower allele frequency in Asians and 
the resultant association was much weaker [19]. The function-
al role of TCF7L2 in the pathogenesis of T2DM is currently 
under thorough investigation. It is a crucial component of Wnt 
signaling and is implicated in β-cell proliferation and insulin 
secretion [20,21]. Furthermore, a recent study reported that 
TCF7L2 is important in maintaining the incretin effect [22].
GWAS
In the year 2007, there was a major breakthrough in identify-
ing genetic risk factors of T2DM through the completion of 
GWAS. In GWAS, hundreds of thousands of single-nucleotide 
polymorphisms (SNPs) are tested for association with a dis-
ease, such as T2DM, in hundreds to thousands of individuals 
[23]. The three major advances that enabled this approach 
were 1) the improved knowledge of human genetic variations 
through the International HapMap project, 2) the technical 
advances in microarray genotyping methods, and 3) the prog-
ress in developing biostatistic methods to handle the large 
amount of data being produced. From the first six GWAS re-
sults reported in 2007, more than ten new genetic loci were re-
ported to modify the risk of T2DM with genome-wide signifi-
cance in Europeans [24-29]. These included variations in or 
near CDKAL1, CDKN2A/2B, SLC30A8, IGF2BP2, HHEX, and 
FTO. The variation in TCF7L2 was confirmed to have the stron-
gest association in Europeans. In addition, the known associa-
tion between variations in KCNJ11 and PPARG with T2DM 
were also replicated. 
  Based on the first GWAS reported by Sladek et al. [24], vari-Park KS
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ations in SLC30A8 and near HHEX were found to be signifi-
cantly associated with T2DM. Genetic variation of SLC30A8 is 
located in 8q24 and encodes an islet-specific zinc membrane 
transporter (ZnT8), which takes part in insulin synthesis and 
secretion [24]. Interestingly, the variation in SLC30A8, rs-
13266634, results in a non-synonymous mutation of the pro-
tein [24]. One locus at 10q23-25 with large linkage disequilib-
rium block encompassing HHEX, IDE, and KIF11 were also 
significantly associated with T2DM. We have reported that 
variations in IDE, which encodes insulin degrading enzyme, 
are associated with the risk of T2DM in Koreans, as well as in 
a meta-analysis [30]. From the DGI study and FUSION study, 
variations in IGF2BP2 and CDKN2A/2B were found to be sig-
nificantly associated with T2DM [25,27]. The IGF2BP2 gene 
located at 3q28, encodes insulin-like growth factor 2 mRNA-
binding protein, which is thought to be involved in insulin 
signaling. A genetic variation located at 9p21 between CDK-
N2A and CDKN2B genes was also associated with T2DM. CD-
KN2A encodes p16
INK4a and its overexpression results in de-
creased β-cell mass in senescent mice [31]. Another variation 
near this locus was independently associated with the risk of 
coronary heart disease due to elevated low density lipoprotein 
Table 1. Genetic variations associated with T2DM and related phenotypes in Koreans
Associated trait Gene symbol Chromo-
some SNP P value Predicted disease mechanism Reference
Diabetes PPARGC1A 4p15 rs3736265 0.04  Insulin resistance, mitochondrial function [55]
KCNJ11 11q15 rs5219 0.01  KATP (Insulin secretion) [45]
PPARGC1B 5q32 rs11959820 0.03  Insulin resistance, mitochondrial function [56]
NRF1 7q32 rs1882094 0.01  Mitochondrial function [47]
PPARG 3p25 rs1801282 0.02  Insulin resistance [46]
IDE 10q23 rs4646957 0.02  Insulin degradation [30]
UCP2 11q13 rs659366 0.02  Mitochondrial function [57]
LEPR 1q31 rs3790419 0.05  Appetite regulation [57]
mtDNA Haplogroup N9a 0.0002  Mitochondrial function [52]
mtDNA 16189C 0.000003  Mitochondrial function [51]
BMI PPARG 3p25 rs1801282 0.01  Insulin resistance [46]
CD14 5q31 rs2569190 0.003  Systemic inflammation [58]
HSD11B1 1q32 rs846908 0.01  Glucocorticoid metabolism [59]
PPARD 6p21 rs9658173 0.03  Insulin resistance [49]
LEPR 1q31 rs1137100 0.02  Appetite regulation [60]
Waist circumference ADIPOR2 12p13 rs1044471 0.02  Insulin resistance [61]
Fasting glucose HSD11B1 1q32 rs701950 0.004 Glucocorticoid metabolism [59]
PPARD 6p21 rs9794 0.04  Insulin resistance [49]
HOMA-IR ADIPOR1 1p36 rs75172865 0.004  Insulin resistance [61]
SBP KCNJ11 11q15 rs886288 <0.001 Insulin secretion [45]
Triglyceride PPARGC1B 5q32 rs11959820 0.02  Insulin resistance, mitochondrial function [56]
PPARG 3p25 rs1801282 0.05  Insulin resistance [46]
PCK1 20q13 rs28359554 0.01  Gluconeogenesis [62]
CD14 5q31 rs2569190 0.01  Systemic inflammation [58]
HDL-C GHRELIN 3p25 rs26311 0.0004  Appetite regulation [48]
PCK1 20q13 rs28359554 0.000003  Gluconeogenesis [62]
T2DM, type 2 diabetes mellitus; SNP, single nucleotide polymorphism; BMI, body mass index; HOMA, homeostasis model assessment; IR, in-
sulin resistance; SBP, systolic blood pressure; HDL-C, high densitiy lipoprotein cholesterol.Genetics of type 2 diabetes
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cholesterol concentration [32,33]. A genetic variation located 
in 6p22.3 of the CDKAL1 gene was first discovered to be sig-
nificantly associated with T2DM through the deCODE study 
[28]. CDKAL1 encodes CDK5 regulatory subunit-associated 
protein 1-like 1 [28], which is thought to inhibit cyclin-depen-
dent kinase 5 (CDK5) activity by binding to the CDK5 activa-
tor p35 [34]. In a recent report, disruption of CDKAL1 in 
mouse β-cells resulted in impaired first-phase insulin secre-
tion [35]. Subjects who had risk variants of CDKAL1 had de-
creased insulin secretion capacity. 
  After the initial GWAS results, meta-analyses with large-
scale replication analyses were performed [36,37]. The DIA-
GRAM consortium, which includes more than 50,000 cases 
and controls, was able to identify six additional genetic loci as-
sociated with T2DM [36]. These included variations in or near 
JAZF1, CDC123-CDMK1D, TSPAN8-LGR5, THADA, AD-
AMTS9, NOTCH2 genes. It should be noted that GWAS car-
ried out in Asians revealed new T2DM genetic loci that were 
not previously reported in Europeans [38-40]. These were in 
or near KCNQ1, UBE2E2 and C2CD4A/4B. The KCNQ1 gene 
encodes a subunit of a voltage-gated potassium channel that is 
expressed in β-cells. The variation in KCNQ1 is thought to 
modulate the risk of T2DM by inducing β-cell dysfunction 
[38,39]. The UBE2E2 gene encodes the ubiquitin-conjugating 
enzyme E2E, which plays an important role in insulin synthe-
sis and secretion under conditions where endoplasmic reticu-
lum stress is increased in β-cells [40]. In an effort to find com-
mon genetic variations affecting fasting plasma glucose, varia-
tion in MTNR1B was found to be significantly associated with 
elevated fasting glucose and risk of T2DM [41-43]. MTNR1B 
encodes the melatonin receptor 2 (MT2) and it is expressed in 
human pancreatic β-cells as well as in the brain [42]. Increased 
expression of MT2 in β-cells is thought to suppress glucose-
stimulated insulin secretion [44]. As of the end of 2010, the re-
sults from the DIAGRAM+ study, with a sample size of 141,000, 
included an additional 12 genetic variations, adding up to a 
total of more than 40 confirmed T2DM genetic risk loci [37]. 
GENETICS OF T2DM IN KOREANS
During the past ten years, my colleagues and I have focused 
on the candidate gene approach to find susceptibility genes for 
T2DM in Koreans. From these efforts, I have reported that 
variations in many genes, e.g., KCNJ11, PPARG, NRF1 and 
IDE are associated with T2DM (Table 1) [30,45-47]. We also 
have investigated the association of candidate genetic varia-
tions with quantitative metabolic traits such as fasting glucose, 
blood pressure, body mass index and dyslipidemia (Table 1) 
[45,48,49]. In addition, we have shown that mtDNA 16189T>C 
variation is associated with an increased risk of T2DM in 
Asians [50,51]. Among the mtDNA haplogroups, we showed 
that mitochondrial haplogroup N9a was significantly associat-
ed with resistance against T2DM, while D5 was significantly 
associated with a risk for T2DM [52]. Association of mito-
Table 2. The most replicated T2DM genetic susceptibility loci confirmed by the initial six GWAS studies and comparison of their 
signals in Koreans [24-29] 
Gene SNP Approach MAF in  
Europeans
OR in  
Europeans
MAF in 
Koreans
OR in  
Koreans
Predicted disease mechanism
PPARG rs1801282(P12A) Candidate gene 0.817 to 0.901 1.148  0.947 1.818 Insulin resistance
KCNJ11 rs5215(E23K) Candidate gene 0.351 to 0.461 1.093  0.456 1.225 KATP (Insulin secretion)
TCF7L2 rs7903146 Linkage analysis fol-
lowed by fine mapping
0.179 to 0.378 2.210  0.025 1.53 β-cell function, incretin effect
HHEX rs1111875 GWAS 0.526 to 0.626 1.172  0.186 1.22 Pancreas development
SLC30A8 rs13266634 GWAS 0.604 to 0.724 1.149  0.585 1.18 Insulin synthesis and secretion
CDKAL1 rs7754840 GWAS 0.293 to 0.373 1.185  0.464 1.24 β-cell function and mass
CDKN2A/2B rs10811661 GWAS 0.810 to 0.844 1.191  0.546 1.25 β-cell function and mass
IGF2BP2 rs4402960 GWAS 0.277 to 0.333 1.139  0.273 1.24 mRNA processing in β-cells
FTO rs8050136 GWAS 0.373 to 0.420 1.116  0.118 1.06 Obesity
The minor allele frequencies (MAF) and odds ratios (OR) of Europeans are adopted from the DIAGRAM+ study [37]. The MAF and OR of 
Koreans are adopted from reference [19]. 
T2DM, type 2 diabetes mellitus; SNP, single nucleotide polymorphism; GWAS, genome-wide association study.Park KS
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chondrial DNA variation with T2DM was not observed in a 
European population [53,54]. For those genes identified by 
GWAS in Caucasians, we also confirmed the significant asso-
ciation between these gene variants with T2DM in Koreans 
(Table 2). Interestingly, the frequencies of risk alleles in Kore-
ans were quite different from those of Caucasians, although 
the odds ratios of each gene variant were similar to those re-
ported in Caucasians. These results suggest that there are im-
portant, but different contributions from genetic variants for 
T2DM between Caucasians and Asians (or Koreans). Fig. 1 
summarizes the susceptibility genes of T2DM in the Korean 
population.
FUTURE PERSPECTIVES
It is evident that the success of the GWAS approach has revo-
lutionized our understanding of the genetic risk factors of 
T2DM and has provided us with better insight into the patho-
genesis of T2DM. Most of the genes identified from the initial 
T2DM GWAS were implicated in a defect in β-cell function, 
rather than increased insulin resistance. It should be noted 
that most genetic variations only have a modest effect and 
their combination only explains less than 10% of the T2DM 
heritability [23]. The underlying hypothesis based on the cur-
rent GWAS and large-scale association studies is that common 
genetic variations are the cause of common complex disor-
ders. Most of the common variations with a higher than 5% 
frequency reside in introns or inter-genic areas and they have 
a relatively small effect size. 
  The current and future strategies to identify T2DM risk loci 
include performing even larger GWAS in different ethnicities. 
This will lead to an increase in the number of common varia-
tions that are associated with T2DM, although the size of their 
effects is small. Finding rare variations with larger effect size is 
a rational strategy to discover additional T2DM genes. Deep 
sequencing around the GWAS signal might yield multiple rare 
variations that have functional consequences. With the advent 
of next generation sequencing technologies, it is now possible 
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Fig. 1.  Susceptibility genes of type 2 diabetes mellitus in Koreans (modified from Textbook of endocrinology and metabolism. 
Korean Endocrine Society. 2nd ed. Seoul: Koonja Publishing; 2011. Section 9, Genetics of diabetes mellitus; p641-4. Used with 
permission) [63].Genetics of type 2 diabetes
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to perform whole exome sequencing. This will allow us to iden-
tify rare functional variation with large impact on a whole exome 
scale. Family studies will be used more frequently as rare vari-
ants will be enriched in the relatives of the index case and the 
affected status would be segregated by the causative genetic 
variation.
  Although the progress in understanding the genetics of 
T2DM has already been immense, it seems that this is just the 
beginning of a new era. Further improvements in our under-
standing of T2DM genetics will eventually lead us to the de-
velopment of new therapeutic and preventive methods as well 
as the basis for individualized medicine. 
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